Pneumococcal infections in elderly patients attending hospital since PCV-13 authorization in Spain
- 11 August 2016
- journal article
- research article
- Published by Taylor & Francis in Infectious Diseases
- Vol. 49 (1) , 71-80
Abstract
Objectives: To study the characteristics and outcomes of pneumococcal infections in patients aged ≥65 years since the authorization of the 13-valent pneumococcal conjugate vaccine (PCV-13) in Spain. Methods: All pneumococcal pneumonias, empyemas or primary bacteraemias treated at two hospitals in Majorca from 2010 to 2015 were included. Clinical variables, serotypes, and antibiotic susceptibility were collected. Results: Two hundred and forty-nine pneumonias, 11 primary bacteraemias, and 2 empyemas in 243 patients were studied; 181 (69.1%) men, median age 76 years (range: 66–99). Seven (2.6%) were pneumococcal-vaccinated. Bacteraemia was present in 127 (61.9%) cases and related to a higher severity, p= 0.02, and not having chronic lung disease, p = 0.002. Ninety-seven (37%) episodes involved complications and 30 (11.5%) patients died. Mortality was related with the presence of complications at admission, p < 0.001. Only septic shock was more frequent in patients ≥65 years during the period 2010–2015 compared to the period 2006–2010: 38 of 262 (14.5%) vs. 17 of 212 (8%), p = 0.02. Most infections (57.6%) were due to PCV-13 serotypes but were not related to a worse prognosis. The proportion of PCV-13 serotypes tended to decrease from 61% (non-invasive) and 80% (invasive) in 2010–2011 to 33% and 47% in 2014–2015. The antibiotic susceptibility remained stable. Conclusions: Rates of pneumococcal vaccination in elderly patients with pneumococcal infections were very low. Except for septic shock, the main outcome variables (including mortality) were similar to the ones observed in the period preceding PCV-13 authorization. PCV-13 serotypes were responsible for most infections although they showed a decreasing trend.Keywords
This publication has 22 references indexed in Scilit:
- Impact of Introduction of Conjugate Vaccines in the Vaccination Schedule on the Incidence of Pediatric Invasive Pneumococcal Disease Requiring Hospitalization in Madrid 2007 to 2011The Pediatric Infectious Disease Journal, 2013
- Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: A 2-year (2007–2009) laboratory-based surveillance in MadridVaccine, 2011
- Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐AreaStreptococcus pneumoniaeResearch (CASPER) StudyClinical Infectious Diseases, 2009
- Emergence ofStreptococcus pneumoniaeSerotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein‐Conjugated Pneumococcal VaccineClinical Infectious Diseases, 2008
- Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate VaccineClinical Infectious Diseases, 2008
- Changing Characteristics of Invasive Pneumococcal Disease in Metropolitan Atlanta, Georgia, after Introduction of a 7-Valent Pneumococcal Conjugate VaccineClinical Infectious Diseases, 2007
- Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccineClinical Microbiology and Infection, 2006
- The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trialsVaccine, 2004
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997